$CTMX
CytomX Therapeutics Inc

2021 Q4 Form 10-Q Financial Statement

#000095017021003053 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $19.73M $17.59M $17.79M
YoY Change 20.51% -1.13% 66.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.456M $11.09M $8.630M
YoY Change 3.34% 28.45% 2.01%
% of Gross Profit
Research & Development $36.58M $29.14M $24.05M
YoY Change 66.19% 21.18% -14.01%
% of Gross Profit
Depreciation & Amortization $675.0K $680.0K $600.0K
YoY Change 12.5% 13.33% -14.29%
% of Gross Profit
Operating Expenses $46.04M $40.23M $32.68M
YoY Change 47.78% 23.09% -10.29%
Operating Profit -$22.64M -$14.90M
YoY Change 52.0% -42.08%
Interest Expense $73.00K $70.00K $200.0K
YoY Change -33.64% -65.0% -90.0%
% of Operating Profit
Other Income/Expense, Net $7.000K -$13.00K -$15.00K
YoY Change -123.33% -13.33% -168.18%
Pretax Income -$26.23M -$22.58M -$14.71M
YoY Change 78.42% 53.53% -37.93%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$26.23M -$22.58M -$14.71M
YoY Change 78.42% 53.53% -37.93%
Net Earnings / Revenue -132.95% -128.41% -82.7%
Basic Earnings Per Share
Diluted Earnings Per Share -$401.6K -$346.3K -$318.4K
COMMON SHARES
Basic Shares Outstanding 65.25M 65.16M 46.19M
Diluted Shares Outstanding 65.21M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $305.2M $236.3M $321.1M
YoY Change -3.45% -26.41% -1.42%
Cash & Equivalents $205.5M $236.3M $176.8M
Short-Term Investments $99.70M $5.000K $144.3M
Other Short-Term Assets $4.285M $3.822M $5.600M
YoY Change -39.65% -31.75% -38.46%
Inventory
Prepaid Expenses
Receivables $790.0K $887.0K $500.0K
Other Receivables $0.00 $0.00 $13.10M
Total Short-Term Assets $310.3M $241.0M $340.3M
YoY Change -4.23% -29.18% 1.65%
LONG-TERM ASSETS
Property, Plant & Equipment $5.960M $6.271M $30.40M
YoY Change -14.24% -79.37% 327.75%
Goodwill $949.0K $949.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $99.97M
YoY Change
Other Assets $901.0K $902.0K $2.300M
YoY Change -58.52% -60.78% 67.27%
Total Long-Term Assets $29.11M $130.2M $34.90M
YoY Change -15.99% 273.17% -7.59%
TOTAL ASSETS
Total Short-Term Assets $310.3M $241.0M $340.3M
Total Long-Term Assets $29.11M $130.2M $34.90M
Total Assets $339.4M $371.2M $375.2M
YoY Change -5.37% -1.06% 0.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.818M $1.516M $3.600M
YoY Change -5.94% -57.89% -20.88%
Accrued Expenses $34.24M $25.17M $23.95M
YoY Change 48.47% 5.1% 16.83%
Deferred Revenue $69.26M $73.09M
YoY Change -7.49%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $106.3M $99.77M $102.0M
YoY Change 5.34% -2.18% 33.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $143.7M $159.8M $225.1M
YoY Change -30.87% -29.02% 23274.87%
Total Long-Term Liabilities $143.7M $159.8M $225.1M
YoY Change -30.87% -29.02% 23274.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $106.3M $99.77M $102.0M
Total Long-Term Liabilities $143.7M $159.8M $225.1M
Total Liabilities $250.0M $259.6M $327.1M
YoY Change -19.05% -20.65% 12.62%
SHAREHOLDERS EQUITY
Retained Earnings -$533.7M -$507.5M
YoY Change 18.58%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $89.38M $111.7M $48.06M
YoY Change
Total Liabilities & Shareholders Equity $339.4M $371.2M $375.2M
YoY Change -5.37% -1.06% 0.71%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$26.23M -$22.58M -$14.71M
YoY Change 78.42% 53.53% -37.93%
Depreciation, Depletion And Amortization $675.0K $680.0K $600.0K
YoY Change 12.5% 13.33% -14.29%
Cash From Operating Activities -$31.19M -$29.70M -$24.70M
YoY Change 79.26% 20.24% 6.01%
INVESTING ACTIVITIES
Capital Expenditures -$245.0K -$268.0K -$800.0K
YoY Change -38.75% -66.5% 33.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00M -$89.30M
YoY Change -100.0% -111.2% -328.39%
Cash From Investing Activities -$245.0K $9.734M -$90.10M
YoY Change -101.26% -110.8% -334.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 683.0K 104.0K 200.0K
YoY Change -94.75% -48.0%
NET CHANGE
Cash From Operating Activities -31.19M -29.70M -24.70M
Cash From Investing Activities -245.0K 9.734M -90.10M
Cash From Financing Activities 683.0K 104.0K 200.0K
Net Change In Cash -30.75M -19.86M -114.6M
YoY Change -303.67% -82.67% -853.95%
FREE CASH FLOW
Cash From Operating Activities -$31.19M -$29.70M -$24.70M
Capital Expenditures -$245.0K -$268.0K -$800.0K
Free Cash Flow -$30.95M -$29.43M -$23.90M
YoY Change 82.04% 23.15% 5.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
dei Entity Central Index Key
EntityCentralIndexKey
0001501989
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
515-3185
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
dei Trading Symbol
TradingSymbol
CTMX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65249116
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236284000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
124260000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
887000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
798000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3822000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7096000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
240998000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
324013000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
99969000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6271000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65249116
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65249116
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48251819
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48251819
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
619117000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6950000
CY2021Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1057000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1167000
CY2021Q3 us-gaap Goodwill
Goodwill
949000
CY2020Q4 us-gaap Goodwill
Goodwill
949000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20170000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22495000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
902000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2172000
CY2021Q3 us-gaap Assets
Assets
371233000
CY2020Q4 us-gaap Assets
Assets
358663000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1516000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2996000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25167000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23059000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
73089000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74869000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
99772000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
100924000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
140770000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
186261000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19017000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21675000
CY2021Q3 us-gaap Liabilities
Liabilities
259559000
CY2020Q4 us-gaap Liabilities
Liabilities
308860000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
499964000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
52000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-507496000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-450115000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
111674000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
371233000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
358663000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17587000
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.90
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17788000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49846000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83989000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29143000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24049000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77615000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90929000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11085000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8634000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29704000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26886000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
40228000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
32683000
us-gaap Operating Expenses
OperatingExpenses
107319000
us-gaap Operating Expenses
OperatingExpenses
117815000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22641000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14895000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57473000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33826000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
200000
us-gaap Investment Income Interest
InvestmentIncomeInterest
182000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1730000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22584000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14710000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57381000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32095000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13911000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22584000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14710000
us-gaap Net Income Loss
NetIncomeLoss
-57381000
us-gaap Net Income Loss
NetIncomeLoss
-18184000
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.35
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.32
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.40
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65208066
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46195121
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63759585
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45992786
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
37000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-63000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
99000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-104000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22547000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14773000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57282000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18288000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107712000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1023000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
518000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3425000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
58000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19243000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130953000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3164000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
37000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22584000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
111674000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51113000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2157000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4013000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
279000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
12205000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
69767000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1179000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
369000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3513000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-320000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15679000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
58829000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
167000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3841000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-63000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14710000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
48064000
us-gaap Profit Loss
ProfitLoss
-57381000
us-gaap Profit Loss
ProfitLoss
-18184000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1921000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1802000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-287000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
341000
us-gaap Share Based Compensation
ShareBasedCompensation
9623000
us-gaap Share Based Compensation
ShareBasedCompensation
11367000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-2325000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-2143000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
89000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
530000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3274000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11509000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1270000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-636000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1358000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-270000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-550000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-9303000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-47271000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
46766000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87839000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22686000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1364000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1864000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
99898000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
189005000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
123996000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
152696000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22734000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38173000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107712000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1818000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3872000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109530000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3872000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
44425000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11615000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189342000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
237201000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
177727000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
183000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Description of the Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
237201000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
177727000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189342000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236284000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176810000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188425000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q3 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
10803000
CY2020Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
10092000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7822000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8362000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2482000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
815000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3509000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
551000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
595000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25167000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23059000
CY2021Q3 us-gaap Revenues
Revenues
17587000
CY2020Q3 us-gaap Revenues
Revenues
17788000
us-gaap Revenues
Revenues
49846000
us-gaap Revenues
Revenues
83989000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
261130000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
47271000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
213859000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
213900000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10929530
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4107097
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
483591
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3047079
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.42
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11505957
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.77
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5708010
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.63
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3164000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3841000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9623000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11367000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1273000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1239000
us-gaap Operating Lease Payments
OperatingLeasePayments
3820000
us-gaap Operating Lease Payments
OperatingLeasePayments
3717000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20170000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22495000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3509000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19017000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21675000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
22526000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24870000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1309000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5273000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5420000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5572000
CY2021Q3 ctmx Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
10116000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27690000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5164000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
22526000
CY2020Q1 ctmx Net Operating Loss Carryback Period
NetOperatingLossCarrybackPeriod
P5Y
CY2020Q1 ctmx Percentage Of Taxable Income From Net Operating Losses For Suspension Of Annual Deduction Limitation
PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation
0.80

Files In Submission

Name View Source Status
0000950170-21-003053-index-headers.html Edgar Link pending
0000950170-21-003053-index.html Edgar Link pending
0000950170-21-003053.txt Edgar Link pending
0000950170-21-003053-xbrl.zip Edgar Link pending
ctmx-20210930.htm Edgar Link pending
ctmx-20210930.xsd Edgar Link pending
ctmx-20210930_cal.xml Edgar Link unprocessable
ctmx-20210930_def.xml Edgar Link unprocessable
ctmx-20210930_htm.xml Edgar Link completed
ctmx-20210930_lab.xml Edgar Link unprocessable
ctmx-20210930_pre.xml Edgar Link unprocessable
ctmx-ex31_1.htm Edgar Link pending
ctmx-ex31_2.htm Edgar Link pending
ctmx-ex32_1.htm Edgar Link pending
ctmx-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending